pd-l1-in-2 — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T78053	PD-L1-IN-2		PD-1/PD-L1
	PD-L1-IN-2, a Naamidine J derivative, serves as a promising antineoplastic immunomodulator by hindering PD-L1 activity. In vivo studies indicate that it suppresses PD-L1 expression and amplifies tumor-infiltrating T-cell...		PD-1/PD-L1
T79739	CYP51/PD-L1-IN-2
	CYP51/PD-L1-IN-2 (compound L20), a quinazoline with antifungal properties, is a potent dual inhibitor targeting both CYP51 (IC50: 0.263 μM) and PD-L1 (IC50: 0.017 μM). The compound promotes early apoptosis in the fungal ...
T6S0071	Fraxinellone		HIF/HIF Prolyl-Hydroxylase , STAT , PD-1/PD-L1
	1. Fraxinellone significantly reduced weight loss and diarrhea in mice and alleviated the macroscopic and microscopic signs of the disease. 2. Fraxinellone exhibited a variety of insecticidal activities including feeding...		HIF/HIF Prolyl-Hydroxylase , STAT , PD-1/PD-L1
T76970	Tagitanlimab
	Tagitanlimab (HBM-9167), a humanized anti-PD-L1 antibody (IgG1κ type), selectively inhibits the PD-L1 and PD-1 interaction. It shows promise for investigation in recurrent or metastatic nasopharyngeal carcinoma (NPC) [1]...
T76899	Adebrelimab
	Adebrelimab (SHR-1316), a humanized IgG4 monoclonal antibody targeting PD-L1 (PD-1/PD-L1), exhibits promising antitumor activity, notably in solid tumors and extensive-stage small-cell lung cancer (SCLC) [1] [2].
T80617	Reozalimab		PD-1/PD-L1
	Rezilimab is a bispecific antibody that targets PD-1/PD-L1 and mediates antibody-dependent cell cytotoxicity (ADCC) in cancer research [1] [2].		PD-1/PD-L1
T76897	Acasunlimab
	Acasunlimab (GEN1046), a bispecific antibody (bsAb) designed to target PD-L1 and 4-1BB, functions by enhancing both T-cell and NK-cell response via conditional 4-1BB stimulation and continuously inhibiting the PD-1/PD-L1...
T36885	BMSpep-57 hydrochloride
	BMSpep-57 hydrochloride, a potent macrocyclic peptide, competitively inhibits PD-1/PD-L1 interaction, exhibiting an IC50 value of 7.68 nM. It binds to PD-L1 with dissociation constants (Kds) of 19 nM and 19.88 nM as dete...
T39106	BMSpep-57
	BMSpep-57, a potent macrocyclic peptide inhibitor, competitively disrupts the PD-1/PD-L1 interaction, demonstrating a significant inhibitory concentration (IC50) of 7.68 nM. It exhibits binding affinity towards PD-L1 wit...
T78902	CYP51/PD-L1-IN-4
	CYP51/PD-L1-IN-4 (compound 14a-2) is a potent dual-target inhibitor of CYP51/PD-L1, displaying IC50 values of 0.17 and 0.021 μM, respectively. This compound demonstrates significant antifungal efficacy and combats drug-r...
T70291	PCC0208018
	PCC0208018 is a novel activator of effector T cells, enhancing T cell proliferation and activation to release interferon gamma (IFN-γ) and interleukin-2 (IL-2) without blocking the programmed cell death 1 (PD-1)/programm...
T79740	CYP51/PD-L1-IN-3
	CYP51/PD-L1-IN-3 (compound L21), a quinazoline with antifungal properties, serves as a dual inhibitor targeting CYP51 (IC50: 0.205 μM) and PD-L1 (IC50: 0.039 μM). This compound promotes early fungal apoptosis within the ...
T79738	CYP51/PD-L1-IN-1
	CYP51/PD-L1-IN-1 (compound L11), a quinazoline with antifungal properties, simultaneously inhibits CYP51 (IC50: 0.884 μM) and PD-L1 (IC50: 0.083 μM). This compound prompts early apoptosis in the fungal cell cycle, marked...
T76945	Cetrelimab
	Cetrelimab (JNJ 63723283; JNJ 3283), a humanized IgG4κ monoclonal antibody (mAb) targeting PD-1, binds to PD-1 (Kd=1.72 nM, HEK293) to prevent its interaction with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, resp...
T82414	Favezelimab	MK-4280
	Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that inhibits the LAG-3/MHC class II interaction and shows potential for use in colorectal cancer (CRC) research, particularly when combined with the PD...
T76997	Socazolimab
	Socazolimab (ZKAB001), an anti-PD-L1 monoclonal antibody, demonstrates enduring safety and efficacy in treating recurrent or metastatic cervical cancer. Additionally, it shows promise for treating small cell lung cancer,...
T37722	Diprovocim-1
	Diprovocim-1 is an agonist of the toll-like receptor 1/2 heterodimer.1It induces TNF-α release in THP-1 cells (EC50= 110 pM), an effect that can be inhibited by anti-TLR1 or anti-TLR2 antibodies. Diprovocim-1 (10 mg/kg) ...
T74393	Antitumor agent-36
	Antitumor agent-36 exhibits strong anti-proliferative and anti-metastasis capabilities, causing significant DNA damage that results in elevated levels of γ-H2AX and p53. It promotes tumor cell apoptosis via the mitochond...
T64022	Antitumor agent-37
	Antitumor agent-37 exhibits potent anti-proliferative and anti-metastatic effects. antitumor agent-37 induces severe DNA damage, leading to high expression of γ-H2AX and p53. antitumor agent-37 induces apoptosis by explo...
T79487	MAO A/HSP90-IN-2		Monoamine Oxidase
	MAO A/HSP90-IN-2 (compound 4-C), a dual inhibitor of HSP90 and MAO A, exhibits IC50 values of 0.016 μM for MAO A and 4.58 μM for HSP90. This compound not only enhances HSP70 expression but also diminishes HER2 and phosph...		Monoamine Oxidase